RBM will market and sell the diagnostic worldwide.
Rules-Based Medicine (RBM) is partnering with Psynova Neurotech to codevelop and commercialize a blood test for schizophrenia. The companies will collaborate on the validation, regulatory approval, and manufacture of the diagnostic, which will be sold by RBM.
The partnership will leverage Psynova’s biomarker discovery efforts with RBM’s protein biomarker platform and CLIA-certified central lab service. The biomarkers for use in this program were discovered through Psynova’s collaborative research program with its cofounder Sabine Bahn, M.D., Ph.D., of the Cambridge Centre for Neuropsychiatric Research (CCNR) at the Institute of Biotechnology, Cambridge University. The Psynova/CCNR research program included the processing of clinical samples on RBM’s HumanMAP®.
“RBM’s technology platform and clinical screening expertise give us a rapid path to bring the candidate biomarkers identified through our research efforts to the benefit of patients,” according to Dr. Bahn. “The Psynova biomarkers not only have the potential to help in the identification of disease subtypes but also in deciding the best treatment options, monitoring patient responses, and facilitating novel approaches to drug discovery.”
